JAK/STAT Signaling

Pebezertinib (BLU 451) is an orally active inhibitor for EGFR.

APT STAT3 is a specific STAT3-binding peptide.

5-FAM-GpYLPQTV-NH2 is a fluorescently labeled peptide and has STAT3 inhibitory activity.

5-FAM-GpYLPQTV-NH2 (TFA) is a fluorescently labeled peptide and has STAT3 inhibitory activity.

Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor.

ErbB-2-binding peptide (HER2-binding peptide) is a tumor-binding peptide.

Becotatug (JMT-101) is an IgG1 antibody targeting EGFR that can also be conjugated to Afatinib and Osimertinib as a synthetic ADC.

Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3.

Imgatuzumab (RG 7160) is a humanized monoclonal antibody against the EGFR.

Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC).

Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2.

Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity.

Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug.

Necitumumab is a human IgG monoclonal antibody directed against EGFR.

Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer.

Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody.

Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody.

Elgemtumab(LJM716) is a fully human IgG monoclonal antibody.

Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor.

SYS6010 is an antibody-drug conjugate (ADC) targeting epidermal growth factor receptor ( EGFR ), which is formed by conjugating the anti-EGFR humanized IgG1 monoclonal antibody Becotatug with the topoisomerase I inhibitor JS-1 via a cleavable tetrapeptide linker.

TQB2102 is a bispecific epitope antibody-drug conjugate targeting HER2, composed of the antibody Rolditamig and the toxin molecule Deruxtecan-d 2.

N3-PEG8-Phe-Lys-PABC-Gefitinib TFA is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC.

HBS-101 is a selectively, orally active, brain-penetrant, Midkine (MDK) inhibitor ( K D = 38.4 nM).

WCY-8-67 TFA is an orally active and selective USP5 inhibitor, with an IC 50 value of 1.33 μM.